Skip to main content

Table 1 Patient characteristics

From: Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer

 

Patients in present study (n= 912)

Patients with HOXB13 expression data (n= 866)

Original cohort (n= 1,780)

Tumor diameter

   ≤20 mm

697 (79)

661 (79)

1,393 (81)

   >20 mm

189 (21)

181 (21)

323 (19)

   Unavailable

26

24

64

Estrogen receptor status

   Positive

686 (78)

651 (77)

1,183 (80)

   Negative

198 (22)

190 (23)

296 (20)

   Unavailable

28

25

301

Progesterone receptor status

   Positive

415 (52)

401 (52)

590 (48)

   Negative

380 (48)

366 (48)

627 (52)

   Unavailable

117

99

563

Tamoxifen treatment

   Yes

473 (52)

447 (52)

886 (50)

   No

439 (48)

419 (48)

894 (50)

  1. Data presented as number of patients (%). Tumor and treatment characteristics of the patients included in the original cohort, patients in the present study and patients in the present study with successful HOXB13 protein expression scoring.